Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/27/2026

1. NVDA
2. OKTA
3. CRM
4. CRWD
5. VEEV
6. P
7. KKR
8. HPQ
9. NTNX
10. SNPS

Go back to Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
CYTOKINETICS (NASDAQ: CYTK) Delayed: 78.71 -0.49 (0.62%)
Previous Close $79.20    52 Week High $13.18 
Open $78.84    52 Week Low $6.00 
Day High $79.13    P/E N/A 
Day Low $78.11    EPS $-1.24 
Volume 455,920